FANCA and triple-negative breast carcinoma: To validate the synthetic lethality of FANCA deficiency with PARPi in human cancer models, we generated FANCA-knockout subclones of the triple-negative breast cancer (TNBC) cell lines MDA-MB-231 and BT-549 using CRISPR/Cas9.